Diabetes drug combo shows Long-Term safety in new study
NCT ID NCT02622113
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at the long-term safety and effectiveness of adding canagliflozin to insulin therapy in adults with type 2 diabetes. A total of 139 people who had completed a previous 16-week study took part. Researchers tracked side effects, blood sugar control, and weight changes over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
139 people
The number who actually took part.
- Start date
-
Dec 2014
- Finished
-
Apr 2016
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
20 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients should complete the week 16 assessments in the double-blind study (TA-7284-11) Exclusion Criteria: * Patients with hereditary glucose-galactose malabsorption or primary renal glucosuria * Patients with severe diabetic complications (proliferative diabetic retinopathy, stage 4 nephropathy, or serious diabetic neuropathy) * Patients with serious renal or hepatic disease * Patients who are the excessive alcohol addicts * Patients who are pregnant, lactating and probably pregnant patients and patients who can not agree to contraception
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Type 2 diabetes mellitus are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Reserch site
Chugoku, Japan
-
Reserch site
Chūbu, Japan
-
Reserch site
Hokkaido, Japan
-
Reserch site
Kanto, Japan
-
Reserch site
Kinki, Japan
-
Reserch site
Kyushu, Japan
-
Reserch site
Tōhoku, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Heartbeat test aims to catch hidden nerve damage in diabetes
- Can Home-Delivered meals help control diabetes?
- New pill takes aim at stubborn blood sugar
- Gene therapy shots aim to save legs from amputation in diabetes
- New pill takes aim at blood sugar in diabetes
- Can AI-Tailored heat warnings shield chronic disease patients from dangerous temperatures?